Cardiac allograft vasculopathy: a review

Area of Science:

• Cardiology
• Immunology
• Transplantation Medicine

Background:

• Cardiac allograft vasculopathy (CAV) is a significant long-term complication following heart transplantation.
• It presents as an accelerated form of coronary artery disease affecting both intramural and epicardial vessels.
• CAV pathogenesis involves immune response, ischemia-reperfusion, infections, immunosuppressants, and traditional risk factors.

Purpose of the Study:

• To review the pathogenesis, morphology, and management strategies for cardiac allograft vasculopathy.
• To elucidate the complex factors contributing to the development and progression of CAV.
• To discuss current and potential therapeutic interventions for CAV.

Main Methods:

• Review of existing literature on cardiac allograft vasculopathy.
• Analysis of pathogenetic mechanisms including immune response, endothelial injury, and repair.
• Examination of diagnostic findings from intracoronary ultrasound studies.
• Evaluation of current and emerging treatment strategies.

Main Results:

• CAV is characterized by unique vascular injury and accelerated coronary disease.
• Pathogenesis involves multiple stimuli leading to repetitive endothelial injury and repair.
• Intracoronary ultrasound shows dual morphology: focal proximal plaques and diffuse distal concentric patterns.
• Apoptosis and impaired vascular remodeling are key mediators.
• Discordant progression between microvascular and epicardial disease is observed.

Conclusions:

• Effective management of CAV requires addressing immune responses and traditional cardiovascular risk factors.
• Strategies targeting T-cell costimulation and adhesion molecules show promise.
• Statins and antiproliferative drugs may slow CAV progression.
• Augmenting nitric oxide bioavailability and novel immunosuppression may be protective.
• Interventional and surgical options have limited efficacy, and retransplantation outcomes are poor.